Literature DB >> 16301644

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.

Mary E Keir1, Yvette E Latchman, Gordon J Freeman, Arlene H Sharpe.   

Abstract

Positive selection during thymocyte development is driven by the affinity and avidity of the TCR for MHC-peptide complexes expressed in the thymus. In this study, we show that programmed death-1 (PD-1), a member of the B7/CD28 family of costimulatory receptors, inhibits TCR-mediated positive selection through PD-1 ligand 1 (PD-L1):PD-1 interactions. Transgenic mice that constitutively overexpress PD-1 on CD4+CD8+ thymocytes display defects in positive selection in vivo. Using an in vitro model system, we find that PD-1 is up-regulated following TCR engagement on CD4+CD8+ murine thymocytes. Coligation of TCR and PD-1 on CD4+CD8+ thymocytes with a novel PD-1 agonistic mAb inhibits the activation of ERK and up-regulation of bcl-2, both of which are downstream mediators essential for positive selection. Inhibitory signals through PD-1 can overcome the ability of positive costimulators, such as CD2 and CD28, to facilitate positive selection. Finally, defects in positive selection that result from PD-1 overexpression in thymocytes resolve upon elimination of PD-L1, but not PD-1 ligand 2, expression. PD-L1-deficient mice have increased numbers of CD4+CD8+ and CD4+ thymocytes, indicating that PD-L1 is involved in normal thymic selection. These data demonstrate that PD-1:PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301644      PMCID: PMC2779139          DOI: 10.4049/jimmunol.175.11.7372

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  The affinity/avidity and length of exposure to the deleting ligand determine dependence on CD28 for the efficient deletion of self-specific CD4+CD8+ thymocytes.

Authors:  H S Teh; S J Teh
Journal:  Cell Immunol       Date:  2001-02-01       Impact factor: 4.868

2.  Critical relationship between TCR signaling potential and TCR affinity during thymocyte selection.

Authors:  P E Love; J Lee; E W Shores
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

3.  RasGRP1 transduces low-grade TCR signals which are critical for T cell development, homeostasis, and differentiation.

Authors:  John J Priatel; Soo-Jeet Teh; Nancy A Dower; James C Stone; Hung-Sia Teh
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

4.  Defective central tolerance induction in NOD mice: genomics and genetics.

Authors:  Silvia Zucchelli; Phil Holler; Tetsuya Yamagata; Matthew Roy; Christophe Benoist; Diane Mathis
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

5.  Maturation versus death of developing double-positive thymocytes reflects competing effects on Bcl-2 expression and can be regulated by the intensity of CD28 costimulation.

Authors:  D J McKean; C J Huntoon; M P Bell; X Tai; S Sharrow; K E Hedin; A Conley; A Singer
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

7.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

8.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

9.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

10.  Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice.

Authors:  H Nishimura; T Honjo; N Minato
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

View more
  56 in total

Review 1.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

Review 4.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

5.  CD55 Is Essential for CD103+ Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity.

Authors:  Michael G Strainic; Jinbo Liu; Fengqi An; Erin Bailey; Andrew Esposito; Jörg Hamann; Peter S Heeger; M Edward Medof
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

6.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

7.  The Autoimmunity-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Autophagy and Alters T Cell Selection.

Authors:  Cornelia Schuster; Kay D Gerold; Kilian Schober; Lilli Probst; Kevin Boerner; Mi-Jeong Kim; Anna Ruckdeschel; Thomas Serwold; Stephan Kissler
Journal:  Immunity       Date:  2015-05-12       Impact factor: 31.745

8.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

9.  Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes.

Authors:  Herbert G Kasler; Eric Verdin
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

Review 10.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.